Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Mahjoubi

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Chirurgie; Memoires De L'Academie De Chirurgie|January 1, 1989
[Neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma. Preliminary results]P Lasser, P Rougier, M Mahjoubi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1995
CPT-11 (irinotecan) in the treatment of colorectal cancerJ P Armand, M Ducreux, M Mahjoubi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancerM Ducreux, M Ychou, J F Seitz, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinumP Rougier, M Mahjoubi, P Lasser, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysisP Rougier, M Ducreux, M Mahjoubi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility studyY Merrouche, J M Extra, D Abigerges, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experienceA Boutan-Laroze, M Mahjoubi, J P Droz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumorsG Catimel, G G Chabot, J P Guastalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessmentF Saliba, R Hagipantelli, J L Misset, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trialsG G Chabot, D Abigerges, G Catimel, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Chirurgie; Memoires De L'Academie De Chirurgie|January 1, 1989
[Neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma. Preliminary results]P Lasser, P Rougier, M Mahjoubi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1995
CPT-11 (irinotecan) in the treatment of colorectal cancerJ P Armand, M Ducreux, M Mahjoubi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancerM Ducreux, M Ychou, J F Seitz, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinumP Rougier, M Mahjoubi, P Lasser, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysisP Rougier, M Ducreux, M Mahjoubi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility studyY Merrouche, J M Extra, D Abigerges, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experienceA Boutan-Laroze, M Mahjoubi, J P Droz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumorsG Catimel, G G Chabot, J P Guastalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessmentF Saliba, R Hagipantelli, J L Misset, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trialsG G Chabot, D Abigerges, G Catimel, et al.
Pageof 3